JP7227374B2 - 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用 - Google Patents

対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用 Download PDF

Info

Publication number
JP7227374B2
JP7227374B2 JP2021532265A JP2021532265A JP7227374B2 JP 7227374 B2 JP7227374 B2 JP 7227374B2 JP 2021532265 A JP2021532265 A JP 2021532265A JP 2021532265 A JP2021532265 A JP 2021532265A JP 7227374 B2 JP7227374 B2 JP 7227374B2
Authority
JP
Japan
Prior art keywords
cells
tcrs
tcr
cell
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021532265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534245A5 (https=
JP2021534245A (ja
Inventor
チェン，シイ
ポーター，エリー
Original Assignee
ルートパス・ジェノミクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルートパス・ジェノミクス，インコーポレーテッド filed Critical ルートパス・ジェノミクス，インコーポレーテッド
Publication of JP2021534245A publication Critical patent/JP2021534245A/ja
Publication of JP2021534245A5 publication Critical patent/JP2021534245A5/ja
Priority to JP2023018149A priority Critical patent/JP7475506B2/ja
Application granted granted Critical
Publication of JP7227374B2 publication Critical patent/JP7227374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021532265A 2018-08-13 2019-08-12 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用 Active JP7227374B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023018149A JP7475506B2 (ja) 2018-08-13 2023-02-09 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862718227P 2018-08-13 2018-08-13
US62/718,227 2018-08-13
US201862725842P 2018-08-31 2018-08-31
US62/725,842 2018-08-31
US201862732898P 2018-09-18 2018-09-18
US62/732,898 2018-09-18
US201962818355P 2019-03-14 2019-03-14
US62/818,355 2019-03-14
US201962823831P 2019-03-26 2019-03-26
US62/823,831 2019-03-26
PCT/US2019/046170 WO2020036875A1 (en) 2018-08-13 2019-08-12 High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018149A Division JP7475506B2 (ja) 2018-08-13 2023-02-09 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用

Publications (3)

Publication Number Publication Date
JP2021534245A JP2021534245A (ja) 2021-12-09
JP2021534245A5 JP2021534245A5 (https=) 2022-08-19
JP7227374B2 true JP7227374B2 (ja) 2023-02-21

Family

ID=69525770

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532265A Active JP7227374B2 (ja) 2018-08-13 2019-08-12 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用
JP2023018149A Active JP7475506B2 (ja) 2018-08-13 2023-02-09 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023018149A Active JP7475506B2 (ja) 2018-08-13 2023-02-09 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用

Country Status (11)

Country Link
US (2) US11208457B2 (https=)
EP (1) EP3837373B1 (https=)
JP (2) JP7227374B2 (https=)
KR (2) KR102543325B1 (https=)
CN (3) CN116298309B (https=)
AU (1) AU2019322834B2 (https=)
CA (1) CA3108439A1 (https=)
IL (2) IL294471B2 (https=)
MX (1) MX2021001763A (https=)
SG (1) SG11202101371TA (https=)
WO (1) WO2020036875A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
CN116298309B (zh) 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
US20210363543A1 (en) * 2018-10-30 2021-11-25 Nantbio, Inc. Self Replicating RNA System
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
WO2023091420A2 (en) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions and methods for t cell engineering
WO2023096890A1 (en) * 2021-11-24 2023-06-01 Rootpath Genomics, Inc. Compositions and methods for polynucleotide assembly
CN115029341A (zh) * 2022-05-23 2022-09-09 立凌生物制药(苏州)有限公司 一种快速克隆配对tcr序列检测方法及其应用
WO2023179795A1 (zh) * 2022-03-25 2023-09-28 立凌生物制药(苏州)有限公司 一种快速且简便地获得正确配对tcr的方法以及获得的tcr
CN114891779A (zh) * 2022-03-31 2022-08-12 立凌生物制药(苏州)有限公司 一种克隆tcr序列的检测方法及其应用
CN115725710A (zh) * 2022-08-09 2023-03-03 立凌生物制药(苏州)有限公司 一种快速克隆肿瘤反应性tcr的方法及其应用
WO2024077185A2 (en) * 2022-10-06 2024-04-11 The Regents Of The University Of California Core-shell hydrogel particles with tunable porosity for digital nucleic acid assays
WO2024206549A2 (en) * 2023-03-29 2024-10-03 Cellicure, Inc. Engineered immune cells and use thereof
CN116913417B (zh) * 2023-04-07 2025-11-28 四川大学 一种dna结合小分子高通量筛选及表征方法
JP2025071533A (ja) * 2023-10-23 2025-05-08 美洛生物科技股▲ふん▼有限公司 新型誘導細胞質インビトロ転写様組成物およびその関連ワクチン医薬設計
JP2025187393A (ja) * 2024-06-13 2025-12-25 株式会社日立製作所 Ｔ細胞受容体（ｔｃｒ）またはｂ細胞受容体（ｂｃｒ）の遺伝子検査方法および遺伝子検査キット

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046205A1 (en) 2015-09-15 2017-03-23 Immunocore Limited Tcr libraries

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6607878B2 (en) 1997-10-06 2003-08-19 Stratagene Collections of uniquely tagged molecules
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
JP2004537313A (ja) 2001-07-31 2004-12-16 クローンテック ラボラトリーズ インク． 細胞内のプロテアーゼ活性を検出する方法
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
MX2008000985A (es) 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
US9029085B2 (en) 2007-03-07 2015-05-12 President And Fellows Of Harvard College Assays and other reactions involving droplets
US8454906B2 (en) 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
EP3150724A1 (en) 2008-12-19 2017-04-05 President and Fellows of Harvard College Particle-assisted nucleic acid sequencing
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP3461910B1 (en) 2012-04-19 2020-08-26 Life Technologies Corporation Nucleic acid amplification
US20150005199A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US20150005200A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US20140378345A1 (en) 2012-08-14 2014-12-25 10X Technologies, Inc. Compositions and methods for sample processing
AU2013302756C1 (en) 2012-08-14 2018-05-17 10X Genomics, Inc. Microcapsule compositions and methods
US11203783B2 (en) * 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
NZ724320A (en) * 2014-03-14 2022-05-27 Adaptimmune Ltd Tcr libraries
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US20150298091A1 (en) 2014-04-21 2015-10-22 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
EP3950944A1 (en) * 2014-09-15 2022-02-09 AbVitro LLC High-throughput nucleotide library sequencing
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
BR112017008877A2 (pt) 2014-10-29 2018-07-03 10X Genomics Inc métodos e composições para sequenciamento de ácido nucleico-alvo
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
AU2016253964B2 (en) * 2015-04-27 2022-07-07 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
KR20190006952A (ko) * 2016-03-31 2019-01-21 라이언 티씨알 피티이. 리미티드 외인성 바이러스-특이적 t 세포 수용체 (tcr)를 발현하는 비-활성화된 t 세포
WO2017177217A2 (en) * 2016-04-08 2017-10-12 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
US20200231974A1 (en) 2017-07-18 2020-07-23 Genovie Ab A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames
WO2019126466A1 (en) 2017-12-22 2019-06-27 Rootpath Genomics, Inc. Compositions and methods for barcoding
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
CN116298309B (zh) 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
EP4061487A4 (en) 2019-11-19 2023-12-20 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046205A1 (en) 2015-09-15 2017-03-23 Immunocore Limited Tcr libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human gene therapy，2017年，Vol.28，p.1158-1168

Also Published As

Publication number Publication date
IL294471A (en) 2022-09-01
JP7475506B2 (ja) 2024-04-26
MX2021001763A (es) 2021-04-19
SG11202101371TA (en) 2021-03-30
US12098181B2 (en) 2024-09-24
IL294471B1 (en) 2024-03-01
US20220135641A1 (en) 2022-05-05
CN116144706A (zh) 2023-05-23
US20210171600A1 (en) 2021-06-10
IL294471B2 (en) 2024-07-01
AU2019322834B2 (en) 2024-07-18
KR20230088518A (ko) 2023-06-19
EP3837373A1 (en) 2021-06-23
CN116298309A (zh) 2023-06-23
KR102543325B1 (ko) 2023-06-13
US11208457B2 (en) 2021-12-28
KR20210057043A (ko) 2021-05-20
CN116298309B (zh) 2024-04-02
CN112840031B (zh) 2023-03-24
CN112840031A (zh) 2021-05-25
CA3108439A1 (en) 2020-02-20
JP2023058615A (ja) 2023-04-25
EP3837373B1 (en) 2024-06-12
WO2020036875A1 (en) 2020-02-20
JP2021534245A (ja) 2021-12-09
EP3837373A4 (en) 2022-07-06
IL280682A (en) 2021-03-25
AU2019322834A1 (en) 2021-03-18
IL280682B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7227374B2 (ja) 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用
US12344651B2 (en) CD19 and CD22 chimeric antigen receptors and uses thereof
EP3283619B1 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
JP2021502979A (ja) Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
EP3368689A2 (en) Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
US20220389406A1 (en) Compositions and methods for t-cell receptor identification
WO2022095903A1 (zh) 靶向pd-1h(vista)的抗肿瘤免疫治疗方法
WO2023174398A1 (en) Synthetic tumor-infiltrating lymphocytes (tils)
US20230272340A1 (en) Compositions and methods for antigen identification
HK40052150B (en) High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
HK40052150A (en) High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
WO2022254337A1 (en) Cd19 and cd22 chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220810

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230209

R150 Certificate of patent or registration of utility model

Ref document number: 7227374

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250